EP1917023A2 — Erythropoietin receptor peptide formulations and uses
Assigned to Affymax Inc · Expires 2008-05-07 · 18y expired
What this patent protects
The present invention relates to peptide compounds that are erythropoietin receptor agonists (EPO-R). The invention also relates to therapeutic methods using said peptide compounds to treat disorders associated with insufficient or defective red blood cell production. The inventi…
USPTO Abstract
The present invention relates to peptide compounds that are erythropoietin receptor agonists (EPO-R). The invention also relates to therapeutic methods using said peptide compounds to treat disorders associated with insufficient or defective red blood cell production. The invention further relates to pharmaceutical compositions, which comprise the peptide compounds of the invention, as well as doses.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.